Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Transitional Cell 13Urinary Bladder Neoplasms 12Ureteral Neoplasms 4Neoplasm Metastasis 3Urologic Neoplasms 2Urogenital Neoplasms 2Carcinoma, Renal Cell 2Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Melanoma 1Male Urogenital Diseases 1Female Urogenital Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Bladder Cancer 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 47Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31trastuzumab deruxtecan 27Specimen Handling 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18Biopsy 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × enfortumab vedotin × Clear all
NCT07287995 2026-04-23

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Recruiting
428 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡